Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Market Closed 05-22 16:00:00 EDT

118.95

+0.94

+0.80%

盘后118.95

+0.000.00%

17:36 EDT

High120.15	Low116.81	Vol2.82M
Open119.06	D1 Closing118.01	Amplitude2.83%
Mkt Cap15.77B	Tradable Cap15.11B	Total Shares132.57M
T/O334.37M	T/O Rate2.22%	Tradable Shares127.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":118.95,"timestamp":1779480000000,"preClose":118.01,"halted":0,"volume":2819648,"hourTrading":{"tag":"盘后","latestPrice":118.95,"preClose":118.95,"latestTime":"17:36 EDT","volume":454990,"amount":54121038.8,"timestamp":1779485787394,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007965426658757713,"floatShares":127000000,"shares":132573424,"eps":-3.404949,"marketStatus":"Market Closed","change":0.94,"latestTime":"05-22 16:00:00 EDT","open":119.06,"high":120.15,"low":116.81,"amount":334365025.64608,"amplitude":0.028303,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.404949,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":118.01,"preHourTrading":{"tag":"盘前","latestPrice":118.01,"preClose":118.01,"latestTime":"09:27 EDT","volume":1007,"amount":116981.936285,"timestamp":1779456463298,"change":0,"changeRate":0,"amplitude":0.053809},"postHourTrading":{"tag":"盘后","latestPrice":118.95,"preClose":118.95,"latestTime":"17:36 EDT","volume":454990,"amount":54121038.8,"timestamp":1779485787394,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0113721837029779,"impliedVol":0.5381,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/GH/wiki","defaultTab":"wiki","newsList":[{"id":"2637750193","title":"Assessing Guardant Health (GH) Valuation After A Strong Share Price Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2637750193","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637750193?lang=en_us&edition=fundamental","pubTime":"2026-05-24 04:15","pubTimestamp":1779567353,"startTime":"0","endTime":"0","summary":"Event context and recent stock performance\nGuardant Health (GH) has drawn investor attention after recent trading, with the stock closing at US$118.95 and showing gains over the past month and past 3 months.\nSee our latest analysis for Guardant Health.\nThe recent move to US$118.95 follows a strong run, with a 7 day share price return of 25.32% and a 1 year total shareholder return of 213.03%, suggesting momentum has been building rather than fading.\nIf Guardant Health’s surge has you thinking...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/assessing-guardant-health-gh-valuation-after-a-strong-share","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/assessing-guardant-health-gh-valuation-after-a-strong-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4551","BK4196","GH","BK4585","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637428193","title":"Guardant Health Chief Legal Officer John G. Saia sells USD 2.11 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637428193","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637428193?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:59","pubTimestamp":1779483544,"startTime":"0","endTime":"0","summary":"Guardant Health Chief Legal Officer John G. Saia reported selling 20,000 shares of common stock on May 20, 2026.The shares sold at weighted average prices ranging from $105.34 to $107.23.Saia’s direct holding fell to 45,950 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL3XrhTn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","SAIA","LU0053671581.USD","BK4588","BK4196","BK4535","GH","LU2065731478.USD","BK4585","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637428533","title":"Guardant Health Co-CEO AmirAli Talasaz disposes of shares worth $22.18 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637428533","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637428533?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:58","pubTimestamp":1779483514,"startTime":"0","endTime":"0","summary":"Guardant Health Co-Chief Executive Officer AmirAli Talasaz reported sales of 209,000 common shares on May 20, 2026, through the Talasaz and Eskandari 2017 Family Trust.The shares sold at prices ranging from USD 100.95 to USD 112.76.Holdings in the trust fell to 1,886,504 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLZkxwW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4551","BK4588","BK4196","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637342882","title":"Guardant Health director Ian T. Clark disposes of shares worth $735,048.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2637342882","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637342882?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:57","pubTimestamp":1779483476,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark reported selling 6,876 shares of common stock on May 20, 2026 at a weighted average price of $106.9.Holdings fell to 2,975 shares, held indirectly through The Thornton-Clark Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLc6MwRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4585","BK4588","BK4535","BK4196","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637434288","title":"Guardant Health director Manuel Hidalgo Medina disposes 1,250 shares worth $133,384.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2637434288","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637434288?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:57","pubTimestamp":1779483449,"startTime":"0","endTime":"0","summary":"Guardant Health director Manuel Hidalgo Medina exercised stock options for 1,000 shares at $32.55 on May 20, 2026.He sold 1,250 shares the same day at about $107.09 per share.His direct holdings ended at 1,639 common shares.He also held 13,029 stock options following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL51Cmzb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health director Manuel Hidalgo Medina disposes 1,250 shares worth $133,384.38","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4585","BK4588","BK4535","BK4196","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637344538","title":"Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637344538","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637344538?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:05","pubTimestamp":1779480300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  22, 2026  (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, ta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300347/0/en/Crinetics-Pharmaceuticals-to-Participate-in-Jefferies-Global-Healthcare-Conference-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","GH","BK4551","LU0029874061.USD","BK4581","BK4588","XLV","BK4585","LU0128526141.USD","PTH","XBI","HCSG","BK4196","LABU","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121559214","title":"Movement Alert｜Guardant Health Falls 8.48% in Pre-Market Trading, Pulling Back After FDA Approval-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1121559214","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121559214?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:04","pubTimestamp":1779447884,"startTime":"0","endTime":"0","summary":"On May 22, Guardant Health fell 8.48% in pre-market trading, trading at $118.01/share, with trading volume of $36,900. The decline comes one session after the stock rallied over 5% following FDA...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148294637","title":"Movement Alert｜Guardant Health Rises 5.01% in Regular Trading, Liquid Biopsy Test Receives FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1148294637","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148294637?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:29","pubTimestamp":1779377377,"startTime":"0","endTime":"0","summary":"On May 21, Guardant Health rose 5.01% in regular trading, trading at $120.65/share, with trading volume of $106 million. The rally was driven by the announcement that the U.S. Food and Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637862333","title":"GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637862333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637862333?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:37","pubTimestamp":1779363424,"startTime":"0","endTime":"0","summary":"GH Research ( ($GHRS) ) has provided an announcement. GH Research PLC will showcase new Phase 2b data on its inhaled psychedelic-based depression t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-new-gh001-phase-2b-data-in-treatment-resistant-depression-at-ascp-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-new-gh001-phase-2b-data-in-treatment-resistant-depression-at-ascp-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4196","BK4551","BK4588","BK4535","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637908821","title":"Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and OS Therapies Incorporated (OSTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637908821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637908821?lang=en_us&edition=fundamental","pubTime":"2026-05-21 00:40","pubTimestamp":1779295209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Guardant Health (GH) and OS Therapies Incorporated (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-guardant-health-gh-and-os-therapies-incorporated-ostx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-guardant-health-gh-and-os-therapies-incorporated-ostx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","LU0128526141.USD","BK4551","BK4581","OSTX","LU0029874061.USD","HCSG","XBI","GH","XLV","LABU","BK4585","BK4196","BK4137","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188757147","title":"Movement Alert｜Guardant Health Rises 10.09% in Regular Trading, FDA Approves Next-Generation Liquid Biopsy Test","url":"https://stock-news.laohu8.com/highlight/detail?id=1188757147","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188757147?lang=en_us&edition=fundamental","pubTime":"2026-05-21 00:16","pubTimestamp":1779293777,"startTime":"0","endTime":"0","summary":"On May 20, Guardant Health rose 10.09% in regular trading, trading at $108.18/share, with trading volume of $146 million. The surge was driven by the U.S. Food and Drug Administration approving the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636844976","title":"FDA approves Guardant360 Liquid CDx test for Guardant Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2636844976","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636844976?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:05","pubTimestamp":1779278749,"startTime":"0","endTime":"0","summary":"FDA clearance granted for Guardant Health’s Guardant360 Liquid CDx, a next-generation liquid biopsy for advanced cancer.The test expands the panel’s genomic footprint by 100x versus the prior Guardant360 CDx.Seven existing FDA-approved companion diagnostic indications for Guardant360 CDx transfer to the new assay.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL8yHv5z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4551","BK4588","BK4196","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636675844","title":"FDA Approves New Guardant360 Liquid Cdx, the Largest FDA-Approved Liquid Biopsy Panel With a 100X Expanded Footprint","url":"https://stock-news.laohu8.com/highlight/detail?id=2636675844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636675844?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:05","pubTimestamp":1779278700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA1CXCGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4196","BK4585","GH","BK4551","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867791","title":"Judge sanctions law firm Quinn Emanuel, citing ethical lapses","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867791?lang=en_us&edition=fundamental","pubTime":"2026-05-20 06:09","pubTimestamp":1779228548,"startTime":"0","endTime":"0","summary":"Judge sanctions law firm Quinn Emanuel, citing ethical lapsesQuinn Emanuel says lawyers, firm apologize to courtMember of firm leadership to address conduct in visits to officesBy Mike Scarcella. Law firm Keller Postman appeals sanctions in Tylenol injury cases","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nL6N41W1BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0012050646.USD","LU2065731478.USD","LU2264538146.SGD","GH","LU0106261612.USD","BK4535","BK4196","BK4585","LU0345770308.USD","LU2065169927.USD","BK4139","BK4551","LU2065171311.SGD","LU2324357040.USD","LU2065171402.SGD","LU0963586101.USD","BK4588","LU1064131342.USD","LU0345770993.USD","LU1988902786.USD","LU2065170008.USD","NTRA","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867781","title":"Guardant Health director Tariq Musa disposes of USD 11,131.36 in shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867781","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867781?lang=en_us&edition=fundamental","pubTime":"2026-05-20 06:03","pubTimestamp":1779228190,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa sold 116 common shares on May 18 at USD 95.96.Holdings fell to 8,662 shares following the sale.The filing also reported the vesting of 250 restricted stock units into 250 common shares on May 15 at USD 0.Derivative holdings were reported at 2,499 restricted stock units after the vesting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL3NX41z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health director Tariq Musa disposes of USD 11,131.36 in shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4588","BK4196","BK4535","BK4585","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636783022","title":"GH Research Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636783022","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636783022?lang=en_us&edition=fundamental","pubTime":"2026-05-19 18:42","pubTimestamp":1779187320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2026 06:42 ET (10:42 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009022","title":"Guardant Health grants 143,898 RSUs to 267 new employees under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009022","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009022?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:51","pubTimestamp":1779137478,"startTime":"0","endTime":"0","summary":"Guardant Health set inducement restricted stock unit grants covering 143,898 common shares for 267 new non-executive hires, with a May 11, 2026 grant date.The awards were issued under the company’s 2023 Employment Inducement Incentive Award Plan.One-third of each RSU vests each year on the anniversary of the vesting commencement date, subject to continued employment on each vesting date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbpnpCc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","GH","BK4535","BK4551","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009029","title":"Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009029?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:51","pubTimestamp":1779137460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA3F5SVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4551","GH","BK4588","BK4535","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636002395","title":"Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636002395","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636002395?lang=en_us&edition=fundamental","pubTime":"2026-05-18 15:31","pubTimestamp":1779089511,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported a wider Q1 2026 net loss of US$18.97 million while advancing GH001 for treatment-resistant depression, including publishing positive Phase 2b data in JAMA Psychiatry and completing key Phase 1 studies.\nAn interesting aspect of this update is how the company has paired clinical progress with expanded financing flexibility, adding a US$200 million at-the-market facility and a US$400 million universal shelf to support its late-stage development plans.\nWith this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","GH","BK4551","BK4585","AIPO","BK4196","BK4535","BK4539","GHRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635511320","title":"Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), GH Research (GHRS) and Doximity (DOCS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635511320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635511320?lang=en_us&edition=fundamental","pubTime":"2026-05-16 09:51","pubTimestamp":1778896283,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA), GH Research (GHRS) and Do...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oruka-therapeutics-orka-gh-research-ghrs-and-doximity-docs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oruka-therapeutics-orka-gh-research-ghrs-and-doximity-docs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","GH","LU0128526141.USD","HCSG","BK4137","BK4539","BK4581","BK4535","BK4196","XLV","DOCS","BK4167","BK4613","GHRS","BK4139","BK4588","LU0029874061.USD","LABU","XBI","BK4551","ORKA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":0.2532},{"period":"1month","weight":0.3282},{"period":"3month","weight":0.1537},{"period":"6month","weight":0.1283},{"period":"1year","weight":2.2105},{"period":"ytd","weight":0.1646}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.022808},{"month":4,"riseRate":0.375,"avgChangeRate":-0.022604},{"month":5,"riseRate":0.625,"avgChangeRate":0.103026},{"month":6,"riseRate":0.714286,"avgChangeRate":0.081894},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction